WHO vaccine-preventable diseases: monitoring system. 2015 global summary

Last updated 15-Jul-2015 (Data received as of 10-Jul-2015)
Next overall update Fall 2015
EPI mother and child logo         
Select a country

Development status: Developed economy GNI / capita (US$): 18'5301 Infant (under 12 months) mortality rate: 32
GDP / capita (US$): 26'3551 Child (under 5 years) mortality rate: 42

Population data in thousands3

  2014  2013  2012  2011  2010  2000  1990  1980 
Total population 1'284  1'287  1'291  1'294  1'299  1'366  1'565  1'474 
Births 14  14  14  14  15  12  21  22 
Surviving infants 14  14  14  14  14  12  20  22 
Pop. less than 5 years 70  71  73  74  73  61  119  109 
Pop. less than 15 years 205  204  203  202  200  245  347  319 
Female 15-49 years 294  297  300  304  308  341  380  372 

Number of reported case

(Click for retrospective incidence data for Estonia)
Diphtheria
Japanese encephalitis
Measles 33 
Mumps 10  12  13  63 
Pertussis 43  55  149  478  1'295  503  87 
Polio*
Rubella 370 
Rubella (CRS)
Tetanus (neonatal)
Tetanus (total)**
Yellow fever
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV). For desagregated data please click on this hyperlink: https://extranet.who.int/polis/public/CaseCount.aspx
it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]).
** Neonatal Tetanus and Total Tetanus cases equality may be the result from a lack of non-Neonatal Tetanus surveillance system.

Percentage target population vaccinated by antigen

Hovering over an antigen reveals its fuller definition
  Most recent coverage survey4  

Official country estimates5

  (Click for retrospective coverage estimates data for Estonia)
Vaccine year result method % card seen                                                
BCG          95  96  97  99  97  99* 
DTP1          95  96  96  96  96  96 
DTP3          93  94  94  93  94  93 
DTP4          92 
IPV1          95 
HepB_BD          16 
HepB3          93  93  94  94  94 
Hib3          93  94  94  93  94 
JapEnc         
MCV1          93  94  94  94  95  93 
MCV2          93  92  94  95  95  89 
PCV1         
PCV3         
Pol3          93  94  94  93  94  93 
Rota1          61 
Rota_last          35 
Rubella1          93  94  94  94  95 
TT2plus         
PAB         
VAD1         
YFV         
  ° indicates that more than 1 survey occurred that year

  Next update: Mid July 2016

WHO-UNICEF estimates6

  (Click for full retrospective WHO-UNICEF coverage estimates data for Estonia)
BCG 95  96  97  99  97  99 
DTP1 95  96  96  96  96  96 
DTP3 93  94  94  93  94  93 
HepB3 93  93  94  94  94 
HepB_BD
Hib3 93  94  94  93  94 
MCV1 93  94  94  94  95  93 
MCV2 93  92  94  95  95  89 
PCV3
Pol3 93  94  94  93  94  93 
Rota_last 32 

Number of districts in the country 15  Proportion of
districts reporting
DTP3 coverage:
% of coverage reports received at national
level vs number of reports expected
100 
   
/
|
|
\
Greater or equal to 90% 100
From 80 to 89% 0
From 50 to 79% 0
Less than 50% 0
Proportion of districts
not reporting DTP3 coverage
0
 

Immunization Schedule (2014 or latest available)

Hovering over an antigen reveals its fuller definition
Vaccine Schedule Entire country Comment
BCG 1-5 days; Yes
DT 3, 4.5, 6 months; 2, 6-7 years; Yes children with contraindication to pertussis component
DTaPHibIPV 3, 4.5, 6 months; 2 years; Yes
DTaPIPV 6-7 years; Yes
HepB birth; 1, 6 months; Yes or 12 years; +1, +6 months
Hib 3, 4.5, 6 months; 2 years; Yes children with contraindication to pertussis component
IPV 3, 4.5, 6 months; 2, 6-7 years; Yes children with contraindication to pertussis component or above Y14 if incomplete vaccination
Influenza_Adult >= 65 years; and pregnant women, adults with chronic diseases, health care workers and other risk groups
Influenza_Pediatric Yes and children with chronic diseases
MMR 1, 13 years; Yes
Rabies Yes pre and post-exposure prevention
Rotavirus 2, 3, 4.5 months; Yes
Td 25 years; Yes every 10 years; children with contrindication to pertussis component and children > 14 years with uncomplete vaccination schedule and post-trauma vaccination
Tdap 15-17 years; Yes

Immunizaton indicators

Indicator Expected answer 2014  2013  2012  2011  2010  2009  2008 

Planning and management

Has the country a Multi-Year Plan (MYP) for immunization? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 
What years does the MYP cover? number 2015-2016  2013-2014  2013-2014  2011-2013  2011-2013  2010-2011  2005-2010 
Nº of districts with microplans that include activities to raise immunization coverage number 15  15  15  15  16  15  15 

System performance

Total Nº districts in country number 15  15  15  15  16  16  15 
Nº districts with DTP3 coverage >=80% number 15  15  15  15  15 
% of districts with DTP3 coverage >=80% From 0 to 100% 100  100  100  100  100 
Nº districts with measles (MCV1) coverage >=95% number 11  10  11      15 
% of districts with MCV1 coverage >=95% From 0 to 100% 60  73  67  73      100 

Safety

Has the country a vaccine adverse events review committee? Yes/No/NR/ND Yes  Yes  Yes  Yes  Yes     
Is there a national system to monitor adverse events following immunization (AEFI)? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 

Finance

Immunization expenditure financed, using Government funds? From 0 to 100%   100  100  100    100  100 

National Immunization Advisory Mechanism

Has the country a standing technical advisory group on immunization (NITAG)? Yes/No/NR Yes  Yes  Yes  Yes  Yes     

Sources

 1  "The 2015 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
 2  World Health Statistics 2013, data for 2012
 3  "United Nations, Population Division. The World Population Prospects - the 2012 revision". New York, 2013.
 4  UNICEF/WHO survey database
 5  If no official estimate is available, the administrative coverage is reported. '*' indicates coverage over 99.5%.
 6  WHO-UNICEF estimates.